Generic AIDS drug deal settled by GSK and Boehringer in S Africa

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.444, 2004-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GSK cuts HIV/AIDS drug prices, Latin America cuts drug deal

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 418, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

South Africa is likely to withdraw approval of nevirapine in the prevention of mother-to-child transmission (MTCT) of HIV infections unless Boehringer Ingelheim produces new data to support the use of the drug in this indication

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 425, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Novartis wins against GSK, `Toprol' faces generic challenge

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 408-409, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

AIDS in Africa: Successes and Challenges

By Wenderlein Dieter

PHARMAKON, Vol. 2, Iss. 5, 2014-09 ,pp. : 335-342

Govi-Verlag

Access to resources Recommend Favorite

GSK bets on the genomic route to drug safety

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 302, 2001-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite